An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO

Summary

The purpose of this study is to examin the efficacy and safety of the study drug recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with moderate-to-severe plaque psoriasis.

Timeline

Start

2024-05-15

Primary completion

2025-01-30

Completion

2025-03-20

Publications

• Cai L, Chen J, Wu L, Duan X, Zhang G, Li Y, Zhang L, Qin L, Zeng T, Wang X, Wang J, Huang K, Ren H, Liu L, Ding Y, Cui Y, Shan Y, Lu J, Tao X, Chen R, Tu Y, Yan M, Zhu X, Qiao N, Meng Z, Wang Y, Cheng F, Yuan Y, Zhu J, Hu X, Guo S, Xia X, Man X, Wu Z, Chen X, Chen G, He Y, Lv D, Feng Y, Deng D, Geng S, Guo Q, Feng W, Zhu X, Liu Y, Lin B, Xia R, Yu C, Fan J, Ji M, Lei T, Yang W, Yang M, Gao Y, Li W, Jiang M, Lou J, Liu Y, Zhou C, Zhang J. SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study. Front Immunol. 2026 Jun 9;17:1810418. doi: 10.3389/fimmu.2026.1810418. eCollection 2026.

Drugs

Indications